During the past decade, Kimitsu Chuo Hospital conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 3 clinical trials were completed, i.e. on average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 3 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kimitsu Chuo Hospital" #1 sponsor was "Janssen Research & Development, LLC" with 3 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan" with 2 trials sponsored, "Abbott Medical Devices" with 1 trials sponsored and "Associations for Establishment of Evidence in Interventions" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kimitsu Chuo Hospital" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Niigata University Medical & Dental Hospital" with 2 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 1 trials as a collaborator and "Japan Lung Cancer Society" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Kimitsu Chuo Hospital" are "Coronary Artery Disease" (2 trials), "Gastrointestinal Stromal Tumor" (2 trials), "Heart Failure" (2 trials), "Metastatic Cancer" (2 trials) and "Prostatic Neoplasms" (2 trials). Many other conditions were trialed in "Kimitsu Chuo Hospital" in a lesser frequency.

Most popular intervention types in "Kimitsu Chuo Hospital" are "Drug" (9 trials), "Biological" (2 trials), "Device" (2 trials), "Procedure" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Abiraterone" (2 trials), "Cetrelimab" (2 trials), "Empagliflozin" (2 trials) and "TAR-200" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kimitsu Chuo Hospital" are 14 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Kimitsu Chuo Hospital". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Kimitsu Chuo Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Kimitsu Chuo Hospital, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".